1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020

 
• By Sue Darcey

A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels. 

FDAEntrance_1200x675
US FDA’s device center would get a significant boost in funding in 2020 under a new House Appropriations Committee, subpanel bill

If a House appropriations subcommittee has its say, theUS Food and Drug Administration’s device center would receive $420m in congressional budget authority in fiscal year 2020 – a raise of 8.5% over the current year’s spending level of $387m. The bill was approved on May 23 by an agriculture and FDA subpanel of the House Committee on Appropriations.

The addition of $219.5m in device user fees slated for 2020, plus the proposed $33m raise, means that device center...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Legislation

MDUFA VI Talks Begin with Familiar Priorities: Innovation, Transparency, Safety

 
• By Elizabeth Orr

At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.

Bipartisan Senate Bill Would Give Patients ‘True Price Tag’ Prior To Care

 
• By Brian Bossetta

Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 
• By Eileen Francis

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

More from Policy & Regulation

Why EU Notified Bodies Need To Alter The Way They Work

 
• By Amanda Maxwell

Without change, the implementation of the MDR and IVDR could hit another wall.

UK MHRA Takes Stock, Seeks CMSO And Reveals Device Innovation Early Access Thinking

 
• By Ashley Yeo

Evolution of the MHRA and its offering to medtechs continues, with the hunt for a visionary chief medical and scientific officer and release of outline plans on early access to innovative devices, building on IDAP learnings.

US FDA Webinar Highlights 506J Expectations Amid Ongoing Supply Chain Vulnerabilities

 
• By Elizabeth Orr

A recent CDRH Learn module urges medical device manufacturers to report potential shortages early, even outside emergencies, to help prevent disruptions. Recent natural disasters underscore the need for resilient supply chains, and reported shortages may be added to an FDA list.